Real-world outcomes from the systemic use of CDK 4/6 inhibitors (CDKIs) in the management of ER positive (+) HER2 negative (-) metastatic breast cancer (mBC).

Karen DeSouza(Nottingham University Hospitals NHS Trust), Sarah Khan(Nottingham University Hospitals NHS Trust), Maria Diossy(Nottingham University Hospitals NHS Trust), Sachin Trivedi(Nottingham University Hospitals NHS Trust), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Daniel Yeo(Nottingham University Hospitals NHS Trust), Anjana Anand(Nottingham University Hospitals NHS Trust), Sumbal Umar(Nottingham University Hospitals NHS Trust), Emma Gore(Nottingham University Hospitals NHS Trust)
Journal of Clinical Oncology
May 20, 2021
10.1200/jco.2021.39.15_suppl.e13031
Cited by 3

Related Papers

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
|The Lancet|2022|664
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|605
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
|The Lancet Oncology|2014|374
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial
|The Lancet Oncology|2015|282